Nadege T Fackche, Ryan K Schmocker, Richard Nudotor, Boateng Kubi, Jordan M Cloyd, Travis E Grotz, Keith F Fournier, Sean P Dineen, Jula Veerapong, Joel M Baumgartner, Callisia N Clarke, Sameer H Patel, Gregory C Wilson, Laura A Lambert, Courtney Pokrzywa, Daniel E Abbott, Byrne Lee, Charles A Staley, Mohammad Y Zaidi, Fabian M Johnston, Jonathan B Greer
INTRODUCTION: Patients with colorectal peritoneal metastases (CRPM) are increasingly treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC). Unfortunately, data identifying preoperative risk factors for poor oncologic outcomes after this procedure are limited. We aimed to determine the prognostic value of preoperative CEA, CA 125, and CA 19-9 on disease progression after CRS/HIPEC. METHODS: Patients with CRPM treated with curative intent CRS/HIPEC from 12 participating sites in the United States from 2000 to 2017 were identified...
February 3, 2024: Annals of Surgical Oncology